Active Studies

In Looking To Treat The Whole Patient, VA Tests Behavioral Health Platform

NeuroFlow, a mental health technology company, has been awarded a $225,000 Phase I Small Business Technology Transfer (STTR) grant from the National Science Foundation to implement its flagship software product EngageBH at the Corporal Michael J. Crescenz VA Medical Center in Philadelphia, PA. Click here to read article in Forbes Magazine.


 

The funds, which recognize the company’s technological innovation in the private sector, will provide the financial means to further measure patient engagement and outcomes while using the platform. In recent years, the funding rate for STTR and Small Business Innovation Research (SBIR) Phase I proposals has been 10-15%.

Investigating the use of precision medicine to treat depression

From Noteworthy Publications- Spring 2018

Dr. David Oslin, a researcher at the Corporal Michael J. Crescenz VA Medical Center in Philadelphia, is testing the use of genetic information to tailor drug therapies for Veterans with major depression. VA Health Services Research and Development and VA's Genomic Medicine Implementation programs are funding a study of precision medicine's role in improving treatment for Veterans with major depressive disorder.

The initiative, PRIME Care (PRecision medicine In MEntal health Care), is led by Dr. David Oslin of the Corporal Michael J. Crescenz VA Medical Center in Philadelphia. It is scheduled to run through June 2022 at more than 20 VA sites across the nation. Click here to read more.